{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:26:56Z","timestamp":1790224016916,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,4,6]]},"DOI":"10.1001\/jama.2021.2454","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T15:42:33Z","timestamp":1617723753000},"page":"1277","source":"Crossref","is-referenced-by-count":127,"title":["Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer"],"prefix":"10.1001","volume":"325","author":[{"given":"Jeffrey A.","family":"Meyerhardt","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber\/Partners CancerCare, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Meyer","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Zemla","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Couture","sequence":"additional","affiliation":[{"name":"H\u00f4tel-Dieu de Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kuebler","sequence":"additional","affiliation":[{"name":"Columbus NCI Community Oncology Research Program, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Bendell","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, Nashville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Illinois CancerCare PC, Peoria, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dequincy","family":"Lewis","sequence":"additional","affiliation":[{"name":"Cone Health Medical Group, Asheboro, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bertagnolli","sequence":"additional","affiliation":[{"name":"Office of the Alliance Group Chair, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[{"name":"West Cancer Center & Research Institute, Germantown, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute, Morgantown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Venook","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Blanke","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Group Chair\u2019s Office, Oregon Health and Science University Knight Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi210017r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v71.1","article-title":"Cancer statistics, 2021.","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"joi210017r2","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"joi210017r3","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/jama.1990.03450110090034","article-title":"Adjuvant therapy for patients with colon and rectal cancer.","volume":"264","author":"NIH Consensus Conference","year":"1990","journal-title":"JAMA"},{"issue":"23","key":"joi210017r4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"joi210017r5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.","volume":"29","author":"Haller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"joi210017r6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview.","volume":"5","author":"Chan","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"issue":"26","key":"joi210017r7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1056\/NEJM200006293422606","article-title":"Chemoprevention of colorectal cancer.","volume":"342","author":"J\u00e4nne","year":"2000","journal-title":"N Engl J Med"},{"key":"joi210017r8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-540-37696-5","article-title":"Cox-2 and cancer chemoprevention: picking up the pieces.","volume":"174","author":"Bertagnolli","year":"2007","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"joi210017r9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1024986220526","article-title":"Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention.","volume":"14","author":"Chan","year":"2003","journal-title":"Cancer Causes Control"},{"issue":"4","key":"joi210017r10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.tpj.6500487","article-title":"A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.","volume":"8","author":"Cross","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"joi210017r11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer.","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"joi210017r12","first-page":"345","article-title":"Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.","volume":"107","author":"Ng","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"joi210017r13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/gut.2010.221143","article-title":"Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.","volume":"60","author":"Coghill","year":"2011","journal-title":"Gut"},{"issue":"13","key":"joi210017r14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer.","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"joi210017r15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model.","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics"},{"issue":"4","key":"joi210017r16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.annonc.2019.12.007","article-title":"Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.","volume":"31","author":"Salem","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"joi210017r19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","article-title":"Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.","volume":"86","author":"Aickin","year":"1996","journal-title":"Am J Public Health"},{"issue":"5","key":"joi210017r20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"joi210017r21","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/gut.2009.203000","article-title":"Effect of aspirin and NSAIDs on risk and survival from colorectal cancer.","volume":"59","author":"Din","year":"2010","journal-title":"Gut"},{"issue":"3","key":"joi210017r22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention.","volume":"16","author":"Drew","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"joi210017r23","first-page":"7407","article-title":"Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer.","volume":"34","author":"Goh","year":"2014","journal-title":"Anticancer Res"},{"issue":"9","key":"joi210017r24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/gutjnl-2014-308260","article-title":"Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.","volume":"64","author":"Li","year":"2015","journal-title":"Gut"},{"issue":"10","key":"joi210017r25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"30","key":"joi210017r26","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.","volume":"28","author":"Midgley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"joi210017r27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1056\/NEJMoa071841","article-title":"Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.","volume":"357","author":"Kerr","year":"2007","journal-title":"N Engl J Med"},{"key":"joi210017r28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1745-6215-12-261","article-title":"The utility of aspirin in dukes C and high risk dukes B colorectal cancer\u2014the ASCOLT study: study protocol for a randomized controlled trial.","volume":"12","author":"Ali","year":"2011","journal-title":"Trials"},{"issue":"11","key":"joi210017r29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S2468-1253(19)30289-4","article-title":"Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.","volume":"4","author":"Joharatnam-Hogan","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"joi210017r30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.dld.2017.12.023","article-title":"Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: a French randomised double-blind phase III trial (PRODIGE 50-ASPIK).","volume":"50","author":"Michel","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"1","key":"joi210017r31","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1186\/s12885-018-5126-7","article-title":"The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2?\u00d7?2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.","volume":"18","author":"Petrera","year":"2018","journal-title":"BMC Cancer"},{"issue":"24","key":"joi210017r32","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1001\/jama.2013.6599","article-title":"Aspirin use and risk of colorectal cancer according to BRAF mutation status.","volume":"309","author":"Nishihara","year":"2013","journal-title":"JAMA"},{"issue":"34","key":"joi210017r33","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.","volume":"31","author":"Domingo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"joi210017r34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.","volume":"367","author":"Liao","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"joi210017r35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamainternmed.2014.511","article-title":"Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.","volume":"174","author":"Reimers","year":"2014","journal-title":"JAMA Intern Med"},{"key":"joi210017r17","volume-title":"Statistical Monitoring of Clinical Trials: A Unified Approach","author":"Proschan","year":"2006"},{"key":"joi210017r18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2778113\/jama_meyerhardt_2021_oi_210017_1617663020.42646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T15:42:42Z","timestamp":1617723762000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2778113"}},"subtitle":["The CALGB\/SWOG 80702 (Alliance) Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.2454","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}